Strategic Partnership – NeoGenomics & Teddy Lab

Teddy Clinical Research laboratory and NeoGenomics Laboratories, announce a strategic partnership to offer integrated clinical trial laboratory services for innovative oncology therapeutic development


Teddy Clinical Research laboratory, a Chinese leading clinical trial laboratory services organization under Tigermed group located in Wuxi, China, and Suzhou NeoGenomics Pharmaceutical Research Co., Ltd., an affiliate of NeoGenomics Laboratories, Inc, a world-leading specialized cancer reference laboratory headquartered in Fort Myers, Florida, USA, are pleased to announced a new strategic partnership by which NeoGenomics will leverage Teddy Clinical Research laboratory’s molecular testing and trial capabilities in their global pharmaceutical trials. Additionally, the partnership will leverage each other’s central lab service capabilities to support discovery and development of innovative oncology drugs around the world. This actively aligns the leadership of two prominent contract research organizations serving the pharmaceutical and biotechnology community with specialized molecular assays and technologies relevant to global clinical studies aimed at developing new drugs and innovative therapies for cancer treatments.

By combining their respective expertise and localized service capabilities, the two companies will offer a full range of specialized central laboratory services to support clinical research for innovative drugs and therapies along with a broad global presence, especially for localized solutions in China and the United States.

Ms. XU Yi, Chief Executive Officer of Teddy Clinical Research Laboratory, said “We are very much looking forward to this strategic partnership. Both parties will be able to provide more innovative, responsive and progressive central laboratory solutions to Biopharmaceutical customers in China and overseas. By working collaboratively with NeoGenomics Laboratories, Inc., Teddy Lab will be able to strengthen our innovative solutions and global presence to better serve domestic and international Biopharmaceutical customers.”

“We are pleased to partner with Teddy Lab to help bring new cancer testing capabilities to support global pharmaceutical clinical trials in China,” Mark Mallon, Chief Executive Officer, NeoGenomics Laboratories, Inc. noted, “With CAP accreditation and a vast experience in multicenter clinical trials, Teddy Lab is a leader in China in multi-platform molecular testing. Together, with NeoGenomics’ global experience and capabilities, we look forward to improving diagnostics and influencing patient care globally.”

About Teddy Clinical Research Laboratory

Teddy Clinical Research Laboratory (Shanghai Guan He Pharmaceutical Technology Co., Ltd.), founded in 2016, is a joint venture between DIAN Diagnostics (300244.SZ), the largest IVD total solution supplier in China, and Tigermed (300347.SZ & HK3347), the largest clinical CRO in China. 

The company strictly adheres to international quality best practices such as CAP and GLP. Teddy lab aims to be a one-stop service solutions in the field of biomarker service, central laboratories, bioanalytical laboratories and companion diagnostics.

Based on the company’s comprehensive translational medicine platforms on genomics, proteomics, bioanalytical laboratories, flow cytometry, pathology, etc. Teddy lab provides more than 2,000 tests for clinical trials from tumor biomarker discovery, validation, PK/PD, safety evaluation and subjects screening. Teddy lab has participated in more than 300 clinical studies to date and has helped the successful launching of many first-in-class drugs in China. It has also accumulated several years of rich project management and laboratory services in various therapeutic area such as oncology, hematology, vaccines, hepatitis, endocrinology, cell therapy, cardiovascular and cerebrovascular diseases.

About Suzhou NeoGenomics Pharmaceutical Research Co., Ltd. and NeoGenomics Laboratories, Inc.

NeoGenomics Laboratories, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics Laboratories, Inc. is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.

Headquartered in Fort Myers, FL, NeoGenomics Laboratories, Inc. operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.



Teddylab Services

We have a wide variety of services based on test platforms supporting routine safety, flow cytometry, anatomic and molecular pathology, PK/BE, and companion diagnostics. We act as a one-stop central lab to provide better services for comprehensive, harmonized clinical trials in this era of progress.

Infectious Disease





Precision Medicine

About Teddylab

A CAP certified and NGSP certified Level I Laboratory, Teddy Clinical Research Laboratory is a joint venture of Tigermed and DiAn Diagnostic, and is dedicated to providing high-quality central lab services for clinical research and development.